ArticleThe European journal of health economics : HEPAC : health economics in prevention and care2020
Economic burden of blindness and visual impairment in Germany from a societal perspective: a cost-of-illness study.
Article in The European journal of health economics : HEPAC : health economics in prevention and care, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- The prevalence of diabetic retinopathy in type-2 diabetes in Pakistan: a systematic review and meta-analysis.Frontiers in clinical diabetes and healthcare · 2026Pooled it
- Cost-effectiveness analysis of myopia management: A systematic review.Frontiers in public health · 2023Pooled it
- Direct and indirect costs associated with declining distance visual acuity: A nationwide longitudinal cost-of-illness study with 11-year follow-up.Acta ophthalmologica · 2026Observational
- Economic burden of blindness and moderate to severe vision impairment in Slovenia.Health economics review · 2026Article
- The economic burden of diabetes-related visual impairment and blindness in Saudi Arabia.Health economics review · 2026Article
- The social and economic burden of retinopathy of prematurity: screening, treatment, and health policy perspectives in a transnational narrative review.Frontiers in pediatrics · 2026Review
- Optogenetic vision restoration in the face of secondary and tertiary remodeling in the rd1 mouse retina.Molecular therapy : the journal of the American Society of Gene Therapy · 2025Article
- Interaction between native and prosthetic visual responses in optogenetic visual restoration.JCI insight · 2025Article
- Impact of Social Vulnerability Index on the Development of Severe Visual Impairment or Blindness From Glaucoma.American journal of ophthalmology · 2024Article
- Assessing the economic burden of vision loss and irreversible legal blindness in Spain (2021-2030): a societal perspective.Health economics review · 2024Article
- Technological Perception with Rural and Urban Differentiation and Its Influence on the Quality of Life of Older People with Age-Related Macular Degeneration.European journal of investigation in health, psychology and education · 2024Article
- Economic evaluation for medical artificial intelligence: accuracy vs. cost-effectiveness in a diabetic retinopathy screening case.NPJ digital medicine · 2024Article
- Risk of visual impairment according to the comorbidity of systemic and ocular diseases.PloS one · 2024Article
- Typologies of dependency, household characteristics, and disparity in formal and informal care use: analysis of community-dwelling long-term care insurance claimants in an urban municipality of China.International journal for equity in health · 2023Article
- [Awareness for glaucoma in the general population].Die Ophthalmologie · 2023Review
- Trends in the Prevalence of Blindness and Correlation With Health Status in Korean Adults: A 10-Year Nationwide Population-Based Study.Journal of Korean medical science · 2023Article
- The Importance of Visual Health-A Representative Population Survey.Deutsches Arzteblatt international · 2022Article
- The economics of vision impairment and its leading causes: A systematic review.EClinicalMedicine · 2022Review
- Photorefraction Screening Plus Atropine Treatment for Myopia is Cost-Effective: A Proof-of-Concept Markov Analysis.Clinical ophthalmology (Auckland, N.Z.) · 2022Article
- Cost-Utility Analysis of a Latanoprost Cationic Emulsion (STN1013001) versus Other Latanoprost in the Treatment of Open-Angle Glaucoma or Ocular Hypertension and Concomitant Ocular Surface Disease in Germany.Clinical ophthalmology (Auckland, N.Z.) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundVisual impairment and blindness cause a considerable and increasing economic burden affecting not only persons with vision loss and their families, but also societies. For the majority of countries, there is no solid database that would allow a comprehensive assessment of costs from a societal perspective. The present study was conducted to fill this gap.
objectivesTo investigate resource utilization of blind or visually impaired people and to assess the economic burden of blindness and visual impairment in Germany.
methodsThis cross-sectional cost-of-illness study measures the economic burden of blindness and visual impairment bottom-up and from a societal perspective. Therefore, blind and visually impaired persons were recruited via national self-help organizations (prevalence-based approach) and interviewed regarding their utilized resources using various survey modes (mixed-mode approach). The observation period was 6 months retrospectively. Utilized resources were valued applying standardized unit costs (macro-costing). Calculations for the study population provided direct and indirect costs per person for a period of 6 months. Further cost per category was extrapolated to 1 year for the general population of Germany. Uncertainty of results was addressed applying univariate deterministic sensitivity analyses.
resultsComplete data were collected from 683 participants (54.84% women; average age: 60.28 ± 17.02 years). Decreasing vision was associated with increasing costs (p < 0.001). Most costs were incurred by informal support from relatives, which was the most important resource for coping with everyday life for people with visual loss. Together with assistive/medical devices and loss of productivity due to disability, informal support accounted for 80% of total costs. Extrapolated to Germany, the annual costs of blindness and visual impairment from a societal perspective amounted to € 49.6 billion. Results of the sensitivity analyses and 95% confidence intervals showed a considerable degree of uncertainty.
conclusionVisual impairment and blindness may cause enormous overall costs from a societal point of view, as shown here for Germany. Our findings on the costs of blindness and visual impairment in Germany add in a number of different ways to the international evidence. In particular, results show that a large proportion of the costs are not obvious per se as it is caused by self-paid deductibles, productivity loss, early retirement and informal support/care by relatives. Further research should make special efforts to investigate these costs precisely as well as their influence factors.
Indexed as
Identifiers
31493181What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.